<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7414743\results\search\disease\results.xml">
  <result pre="courier ; font-style : italic;} BMC Infect DisBMC Infect. DisBMC" exact="Infectious" post="Diseases1471-2334BioMed CentralLondon pmcid: 74147435285 doi: 10.1186/s12879-020-05285-z : Research Article"/>
  <result pre="modeling analysis http://orcid.org/0000-0001-8780-3612SkaathunBrittbskaathun@health.ucsd.edu1BorquezAnnick1Rivero-JuarezAntonio2MehtaSanjay R.1TellezFrancisco3CastaÃ±o-CarracedoManuel4MerinoDolores5PalaciosRosario6MacÃ­asJuan7RiveroAntonio2MartinNatasha K.18[1], grid.266100.30000 0001 2107 4242Division of" exact="Infectious" post="Diseases and Global Public Health, University of California San"/>
  <result pre="analysis http://orcid.org/0000-0001-8780-3612SkaathunBrittbskaathun@health.ucsd.edu1BorquezAnnick1Rivero-JuarezAntonio2MehtaSanjay R.1TellezFrancisco3CastaÃ±o-CarracedoManuel4MerinoDolores5PalaciosRosario6MacÃ­asJuan7RiveroAntonio2MartinNatasha K.18[1], grid.266100.30000 0001 2107 4242Division of Infectious" exact="Diseases" post="and Global Public Health, University of California San Diego,"/>
  <result pre="University of California San Diego, [2], grid.411901.c0000 0001 2183 9102Infectious" exact="Diseases" post="Unit, Instituto Maimonides de Investigaciones Biomedicas de Cordoba (IMIBIC),"/>
  <result pre="Universitario Reina Sofia de Cordoba, Universidad de Cordoba, [3], grid.7759.c0000000103580096Infectious" exact="Diseases" post="Unit Hospital Universitario de Puerto Real, Instituto de InvestigaciÃ³n"/>
  <result pre="de la Provincia de CÃ¡diz. Universidad de CÃ¡diz, [4], grid.411457.2Infectious" exact="Diseases" post="Unit, Hospital Regional Universitario de MÃ¡laga, [5], [6], grid.411062.00000"/>
  <result pre="Regional Universitario de MÃ¡laga, [5], [6], grid.411062.00000 0000 9788 2492Infectious" exact="Diseases" post="Unit, Hospital Universitario Virgen de la Victoria. Complejo Hospitalario"/>
  <result pre="a credit line to the data. Abstract Background Scale-up of" exact="hepatitis C" post="virus (HCV) treatment for HIV/HCV coinfected individuals is occurring"/>
  <result pre="annually from 2020 would increase the number of new HCV" exact="infections" post="among PWLH by 28% and reduce the number of"/>
  <result pre="PWLH by 28% and reduce the number of new HCV" exact="infections" post="by 39% among the broader population by 2030. Conclusion"/>
  <result pre="treatment among PLWH and the broader population at risk. Keywords" exact="Hepatitis" post="C virus Prevention Microelimination HIV Direct-acting antivirals Funding http://dx.doi.org/10.13039/100000026National"/>
  <result pre="(WHO) released elimination targets including an 80% reduction in new" exact="hepatitis C" post="virus (HCV) infections and 65% reduction in HCV related"/>
  <result pre="including an 80% reduction in new hepatitis C virus (HCV)" exact="infections" post="and 65% reduction in HCV related mortality by 2030"/>
  <result pre="HCV elimination is possible due to the advent of highly-effective," exact="short" post="duration, tolerable, all-oral HCV direct-acting antiviral therapies (DAAs) which"/>
  <result pre="focused efforts at microelimination (elimination among targeted populations, settings, or" exact="limited" post="geographical areas) among key populations such as people living"/>
  <result pre="[17]. PWID are the main group at risk for HCV" exact="infection" post="in Spain, and the main group at risk for"/>
  <result pre="2015, a multicentre prospective observational cohort of HIV-infected patients with" exact="chronic" post="HCV infection from 21 reference centers in Andalusia, Spain"/>
  <result pre="multicentre prospective observational cohort of HIV-infected patients with chronic HCV" exact="infection" post="from 21 reference centers in Andalusia, Spain was established"/>
  <result pre="HCV coinfection transmission among PWID [21â€&quot;23], and HCV prevention among" exact="HIV-positive" post="MSM [24â€&quot;27], to our knowledge no published study has"/>
  <result pre="microelimination within HIV+ individuals when the vast majority of new" exact="infections" post="are among PWID. One study examined elimination among HIV+"/>
  <result pre="(only HIV) among PWID (Fig. 1b). The joint model incorporated" exact="infection" post="with HIV only (uninfected, HIV-infected undiagnosed, HIV-infected diagnosed and"/>
  <result pre="HCV. Finally, the model incorporates biological interactions between HCV and" exact="HIV infection," post="such that HIV-infection reduces the probability of HCV spontaneous"/>
  <result pre="HCV spontaneous clearance (TableÂ 1) [2, 32]. Additionally, we assumed" exact="HIV infection" post="increases HCV transmissibility through elevated HCV viral loads if"/>
  <result pre="spontaneous clearance (TableÂ 1) [2, 32]. Additionally, we assumed HIV" exact="infection" post="increases HCV transmissibility through elevated HCV viral loads if"/>
  <result pre="we assumed HIV infection increases HCV transmissibility through elevated HCV" exact="viral" post="loads if the individual is not on ART [46,"/>
  <result pre="at risk of reinfection) and incorporated a fixed incidence of" exact="infection" post="and reinfection. As there are currently no restrictions on"/>
  <result pre="successful treatment. Individuals who fail treatment (do not attain sustained" exact="viral" post="response SVR) are not retreated. Fig. 1 Model schematics"/>
  <result pre="inject drugs. MSM: men who have sex with men. HCV:" exact="hepatitis C" post="virus. SVR: sustained viral response Table 1 Model parameters"/>
  <result pre="have sex with men. HCV: hepatitis C virus. SVR: sustained" exact="viral" post="response Table 1 Model parameters and Sources Calibration Data"/>
  <result pre="and Source Number of diagnosed and in care HIV-infected and" exact="chronic" post="HCV coinfected (HIV+/HCV+) in 2015 3075 as observed in"/>
  <result pre="with 2669 [range 2402â€&quot;2936] with a history of PWID HCV" exact="chronic" post="prevalence among PWID injecting for 45% [sampled uniformly from"/>
  <result pre="spontaneous clearance rates by HIV-status in the below table. HCV" exact="chronic" post="prevalence among PWID injecting for &amp;gt;â€‰10â€‰years in 2010 60%"/>
  <result pre="[sampled uniformly 30â€&quot;50%]. Values from Folch et al. [29] HCV" exact="chronic" post="prevalence among HIV+ ever PWID in 2015 54% [sampled"/>
  <result pre="[sampled uniformly 30â€&quot;34%] as observed in the HERACLES cohort [17]" exact="General" post="Parameters Parameter Definition Symbol Sampled Value and 95% Interval"/>
  <result pre="Sampled Value and 95% Interval Sampling Distribution Source Sustained HCV" exact="viral" post="response, monoinfected on DAAs 1- fmd 0.9 [2] Sustained"/>
  <result pre="response, monoinfected on DAAs 1- fmd 0.9 [2] Sustained HCV" exact="viral" post="response, coinfected on DAAs 1- fcd 0.948 HERACULES cohort"/>
  <result pre="coinfected on DAAs 1- fcd 0.948 HERACULES cohort Sustained HCV" exact="viral" post="response, monoinfected pre-DAAs 1- fmpd 0.52 (0.45â€&quot;0.60) Uniform [0.45â€&quot;0.60]"/>
  <result pre="weighted by genotype and genotype distribution [30, 31]. Sustained HCV" exact="viral" post="response, coinfected pre-DAAs 1- fcpd 0.30 (0.20.-0.39) Uniform [0.20â€&quot;0.40]"/>
  <result pre="(0.20â€&quot;0.32) Uniform [1/5â€&quot;1/3] [34, 35] Excess death rate due to" exact="chronic" post="HCV mono-infection per year Î¼HCV 0.00169 (0.0016â€&quot;0.00181) Uniform [0.00154â€&quot;0.00183]"/>
  <result pre="(0.0016â€&quot;0.00181) Uniform [0.00154â€&quot;0.00183] [36] Relative risk of death due to" exact="chronic" post="HCV for HIV/HCV coinfection not on HIV treatment compared"/>
  <result pre="Uniform [0.0038â€&quot;0.0046] [36, 37] Relative risk of death due to" exact="chronic" post="HCV for HIV/HCV coinfection on HIV treatment compared to"/>
  <result pre="injecting for those on ART RRHIVi 0.50 (0.27â€&quot;0.72) Uniform [0.25â€&quot;0.75]" exact="Limited" post="data. One modeling study in Vancouver estimated 44% efficacy"/>
  <result pre="HIV transmission through sex during the latent untreated stage of" exact="infection" post="Î²HIVsÂ =â€‰1/6* Î²HCV [21] Proportion spontaneous HCV clearance among"/>
  <result pre="the proportion of HIV+ MSM who are diagnosed, by the" exact="primary" post="HCV incidence among HIV-infected MSM. Number of HIV-infected MSM"/>
  <result pre="HIV+ MSM who are diagnosed 0.761 (0.751â€&quot;0.771) Uniform [0.75â€&quot;0.772] [53]" exact="Primary" post="HCV incidence among HIV-infected MSM (per 100 person-years) 1.17"/>
  <result pre="(clinicaltrial.gov: NCT02511496), a prospective cohort of 3075 HIV-infected individuals with" exact="chronic" post="HCV infection from 21 reference hospitals set up in"/>
  <result pre="a prospective cohort of 3075 HIV-infected individuals with chronic HCV" exact="infection" post="from 21 reference hospitals set up in March 2015,"/>
  <result pre="main objective of evaluating the current status and follow-up of" exact="chronic" post="HCV infection in patients coinfected with HIV in Andalusia."/>
  <result pre="of evaluating the current status and follow-up of chronic HCV" exact="infection" post="in patients coinfected with HIV in Andalusia. Information from"/>
  <result pre="for the model: the number of HIV individuals diagnosed with" exact="chronic" post="HCV and with a history of injecting drugs in"/>
  <result pre="who are PWID, the proportion of HIV-infected ever PWID with" exact="chronic" post="HCV infection who previously failed treatment in 2015, the"/>
  <result pre="PWID, the proportion of HIV-infected ever PWID with chronic HCV" exact="infection" post="who previously failed treatment in 2015, the HCV treatment"/>
  <result pre="model was calibrated to the following epidemiological data from Spain:" exact="chronic" post="HCV prevalence of 45 and 60% among PWID who"/>
  <result pre="PWID who initiated injecting â€‰10â€‰years ago, respectively in 2010Â [29]," exact="chronic" post="HCV prevalence among HIV+ ever PWID (PWID and ex-PWID)"/>
  <result pre="of available data, we used global pooled estimates of HCV" exact="primary" post="incidence among HIV+ MSM (see Table 1 and supplement"/>
  <result pre="a drop in the contribution of PWID to new HIV" exact="infections" post="between 2004 and 05 and 2010â€&quot;11, which could be"/>
  <result pre="leading to fewer newly initiated PWID at risk instead of" exact="lower" post="transmission risk [28, 60]. Given these data, we incorporated"/>
  <result pre="from underlying distributions (Table 1) using Latin Hybercube Sampling a" exact="total" post="of 500 times. The model was calibrated to the"/>
  <result pre="2015 to 2017). The proportion of individuals treated was significantly" exact="lower" post="among PWID at 55% (defined as on OST or"/>
  <result pre="from 2020 We model the impact on HCV incidence and" exact="chronic" post="prevalence among PLWH and overall until 2030 with the"/>
  <result pre="of 10.5% among diagnosed HIV/HCV coinfected individuals) Univariate sensitivity analyses" exact="Multiple" post="univariate sensitivity analyses were performed to test the sensitivity"/>
  <result pre="uncertainty in future SVR rates, we evaluate the impact of" exact="lower" post="DAA SVR (85 and 90% vs. 95% at baseline)."/>
  <result pre="rate of injecting initiation did not decline in 2010. Results" exact="Epidemic" post="prior to DAA scale-up in 2015 The model fit"/>
  <result pre="number of newly diagnosed HIV/HCV coinfections (defined as new HCV" exact="infections" post="among HIV-diagnosed as well as new diagnoses of HIV"/>
  <result pre="diagnoses of HIV among HCV-infected individuals, some who may have" exact="acquired" post="their HCV prior to their HIV infection) was projected"/>
  <result pre="prior to their HIV infection) was projected to be 200" exact="infections" post="(2.5â€&quot;97.5% interval 139â€&quot;299) in 2015, the majority (84%) among"/>
  <result pre="of injecting drug use. Among PWID, we project that HCV" exact="chronic" post="prevalence was increasing among PWID in Andalusia due to"/>
  <result pre="injecting, leading to an aging cohort with higher burden of" exact="disease" post="(Supplementary Figure 3). In 2015, an estimated mean of"/>
  <result pre="2015, an estimated mean of 46% of all prevalent HCV" exact="infections" post="and an estimated mean of 12% of incident HCV"/>
  <result pre="infections and an estimated mean of 12% of incident HCV" exact="infections" post="among PWID were among HIV+ PWID. Modeled impact of"/>
  <result pre="line), and would moderately increase the number of new HCV" exact="infections" post="(diagnosed and undiagnosed) among PLWH (meanâ€‰âˆ’â€‰12% relative reduction (95%I:"/>
  <result pre="continuing current rates would reduce the number of new HCV" exact="infections" post="by a relative 29% (95%I: 19â€&quot;37%) by 2030. Among"/>
  <result pre="(Fig.Â 3), the scale-up was projected to marginally reduce both" exact="chronic" post="HCV prevalence (mean relative reduction of 5% [95%I: 1â€&quot;7%])"/>
  <result pre="9% [95%I: âˆ’â€‰0.09 to 10%]) from 2015 to 2019. Negative" exact="lower" post="bounds correspond to scenarios where HCV chronic prevalence slightly"/>
  <result pre="to 2019. Negative lower bounds correspond to scenarios where HCV" exact="chronic" post="prevalence slightly increased from 2015 to 2019 due to"/>
  <result pre="Fig. 3 Mean model projections of the (a) number of" exact="chronic" post="HCV infections (b) number of new chronic HCV infections"/>
  <result pre="Mean model projections of the (a) number of chronic HCV" exact="infections" post="(b) number of new chronic HCV infections with observed"/>
  <result pre="(a) number of chronic HCV infections (b) number of new" exact="chronic" post="HCV infections with observed scaled-up DAA treatment rates from"/>
  <result pre="of chronic HCV infections (b) number of new chronic HCV" exact="infections" post="with observed scaled-up DAA treatment rates from 2015 in"/>
  <result pre="green line), an increase in the number of new HCV" exact="infections" post="by a relative 31% (95%I: 26â€&quot;38%) among HIV+ populations"/>
  <result pre="6), and a reduction in the number of new HCV" exact="infections" post="overall by a relative 36% (95%I: 35â€&quot;41%) 2015â€&quot;2030 (Fig."/>
  <result pre="4b, green line). Fig. 4 Mean model projections for HCV" exact="chronic" post="prevalence and incidence among people who inject drugs (a,"/>
  <result pre="withÂ varying sustained virologic response rates (solid lines)Â and a" exact="stable" post="PWID population sizeÂ (dashed line) Discussion Our analysis indicates"/>
  <result pre="on reducing the number of existing and newly diagnosed HCV" exact="infections" post="among PLWH, but will not achieve microelimination among HIV/HCV"/>
  <result pre="previous study conducted in France modeled the HCV epidemic among" exact="HIV-positive" post="patients from all risk groups, finding that elimination was"/>
  <result pre="the monoinfected HCV population, assuming a low fixed incidence among" exact="HIV-positive" post="PWID. Due to a combination of biological, behavioral, and"/>
  <result pre="first few years of injecting initiation and prior to their" exact="HIV infection" post="[65]. Hence, the incidence of acute HCV among HIV+"/>
  <result pre="few years of injecting initiation and prior to their HIV" exact="infection" post="[65]. Hence, the incidence of acute HCV among HIV+"/>
  <result pre="prior to their HIV infection [65]. Hence, the incidence of" exact="acute" post="HCV among HIV+ PWID is low and may underestimate"/>
  <result pre="our analysis has a number of limitations. Firstly, we are" exact="limited" post="by uncertainty in underlying epidemiological data. To account for"/>
  <result pre="firstly, guidelines do not mention retreatment restrictions, and secondly, accelerated" exact="disease" post="progression among HIV/HCV coinfected individuals provides a strong indication"/>
  <result pre="includes treatment as prevention benefits among PWID. Most incident HCV" exact="infections" post="in Spain are among PWID, and the majority of"/>
  <result pre="traditionally MSM have been the focus of many studies of" exact="acute" post="HCV among HIV-infected individuals, this is because PWID usually"/>
  <result pre="early on in their injecting careers and prior to their" exact="HIV infection" post="[54]. As such, our study primarily focused on treatment"/>
  <result pre="on in their injecting careers and prior to their HIV" exact="infection" post="[54]. As such, our study primarily focused on treatment"/>
  <result pre="HCV reinfection incidence data from HIV+ MSM and pooled HCV" exact="primary" post="incidence data from HIV+ MSM because Andalusia-specific data were"/>
  <result pre="in terms of relative reductions in incidence (which is our" exact="primary" post="outcome), although it would mean that the absolute numbers"/>
  <result pre="treatment scale-up is leading to observed reductions in HCV incidence" exact="or chronic" post="prevalence, and to confirm whether Andalusia is on track"/>
  <result pre="scale-up is leading to observed reductions in HCV incidence or" exact="chronic" post="prevalence, and to confirm whether Andalusia is on track"/>
  <result pre="among PWID, both moninfected and coinfected alike. Eliminating HCV from" exact="HIV-positive" post="populations will require efforts to prevent HCV infection among"/>
  <result pre="HCV from HIV-positive populations will require efforts to prevent HCV" exact="infection" post="among PWID prior to their HIV infection, and therefore"/>
  <result pre="efforts to prevent HCV infection among PWID prior to their" exact="HIV infection," post="and therefore elimination efforts should focus on combination prevention"/>
  <result pre="number of new HIV/HCV diagnosed active PWID, (C) number of" exact="chronic" post="HCV infections among active PWID, and (D) number of"/>
  <result pre="new HIV/HCV diagnosed active PWID, (C) number of chronic HCV" exact="infections" post="among active PWID, and (D) number of new chronic"/>
  <result pre="HCV infections among active PWID, and (D) number of new" exact="chronic" post="HCV infections among active PWID with observed scaled-up DAA"/>
  <result pre="among active PWID, and (D) number of new chronic HCV" exact="infections" post="among active PWID with observed scaled-up DAA treatment rates"/>
  <result pre="Figure S3. Model projections (mean and 95% intervals) for HCV" exact="chronic" post="prevalence and incidence among people who inject drugs (A,C)"/>
  <result pre="Figure S4. Comparison of the model projected trends in HCV" exact="chronic" post="prevalence among HIV+ individuals with a history of injecting"/>
  <result pre="HCV prevalence against the data. HIV prevalence (A,B) and HCV" exact="chronic" post="prevalence (C,D) shown among people who inject drugs by"/>
  <result pre="S6. Mean model projections of the number of new HCV" exact="infections" post="among HIV+ MSM and PWID in Andalusia, Spain if"/>
  <result pre="10% of HCV monoinfected PWID were treated annually. Abbriviations HCV" exact="Hepatitis" post="C virus PLWH People living with HIV PWID People"/>
  <result pre="have sex with men DAAs Direct-acting antiviral therapies SVR Sustained" exact="viral" post="response OST Opiate substitution therapy Publisherâ€™s Note Springer Nature"/>
  <result pre="Drug Abuse [grant number R01 DA037773]. NM and BSÂ had" exact="partial" post="support from the University of California San Diego Center"/>
  <result pre="NM was supported byÂ the National Institute of Allergy and" exact="Infectious" post="Diseases and National Institue for Drug AbuseÂ [grant number"/>
  <result pre="was supported byÂ the National Institute of Allergy and Infectious" exact="Diseases" post="and National Institue for Drug AbuseÂ [grant number R01Â"/>
  <result pre="the Plan Nacional de Iâ€‰+â€‰Dâ€‰+â€‰I, and cofinanced by the ISCIII-SubdirecciÃ³n" exact="General" post="de EvaluaciÃ³n and the Fondo Europeo de Desarrollo Regional"/>
  <result pre="the Plan Nacional de Iâ€‰+â€‰Dâ€‰+â€‰I, and cofinanced by the ISCIII-SubdirecciÃ³n" exact="General" post="de EvaluaciÃ³n and the Fondo Europeo de Desarrollo Regional"/>
  <result pre="SRM serves as an Associate Editorial Board Member of BMC" exact="Infectious" post="Diseases. References References 1.WHO. Global health sector strategy on"/>
  <result pre="Infectious Diseases. References References 1.WHO. Global health sector strategy on" exact="viral hepatitis" post="2016â€&quot;2021: towards ending viral hepatitis. Geneva: World Health Organization."/>
  <result pre="Diseases. References References 1.WHO. Global health sector strategy on viral" exact="hepatitis" post="2016â€&quot;2021: towards ending viral hepatitis. Geneva: World Health Organization."/>
  <result pre="Global health sector strategy on viral hepatitis 2016â€&quot;2021: towards ending" exact="viral hepatitis." post="Geneva: World Health Organization. WHO Press; 2016. 2.Yang HJ,"/>
  <result pre="the efficacy and safety of sofosbuvir for the treatment of" exact="hepatitis C" post="virus infection. (2210â€&quot;7711 (Electronic)). 3.NaggieSCooperCSaagMWorkowskiKRuanePTownerWJet al.Ledipasvir and Sofosbuvir for"/>
  <result pre="and safety of sofosbuvir for the treatment of hepatitis C" exact="virus infection." post="(2210â€&quot;7711 (Electronic)). 3.NaggieSCooperCSaagMWorkowskiKRuanePTownerWJet al.Ledipasvir and Sofosbuvir for HCV in"/>
  <result pre="et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human" exact="Immunodeficiency" post="Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine"/>
  <result pre="6.Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL." exact="Hepatitis" post="C virus treatment as prevention in an extended network"/>
  <result pre="Lima VD, Lima Vd Fau - Foster GR, et al." exact="Hepatitis" post="C virus treatment for prevention among people who inject"/>
  <result pre="al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for" exact="hepatitis C" post="in patients co-infected with HIV-1: a randomized trial. (1538â€&quot;3598"/>
  <result pre="K, et al. Sofosbuvir and Velpatasvir for the Treatment of" exact="Hepatitis" post="C Virus in Patients Coinfected With Human Immunodeficiency Virus"/>
  <result pre="Treatment of Hepatitis C Virus in Patients Coinfected With Human" exact="Immunodeficiency" post="Virus Type 1: An Open-Label, Phase 3 Study. (1537â€&quot;6591"/>
  <result pre="Accessed 26 Feb 2019. 15.BoerekampsAvan den BerkGELauwFNLeytenEMvan KasterenMEvan EedenAet al.Declining" exact="hepatitis C" post="virus (HCV) incidence in Dutch human immunodeficiency virus-positive men"/>
  <result pre="EedenAet al.Declining hepatitis C virus (HCV) incidence in Dutch human" exact="immunodeficiency" post="virus-positive men who have sex with men after unrestricted"/>
  <result pre="Merino D, Neukam K, Rios-Villegas MJ, et al. Dimension of" exact="chronic hepatitis C" post="virus in HIV-infected patients in the interferon-free era: an"/>
  <result pre="D, Neukam K, Rios-Villegas MJ, et al. Dimension of chronic" exact="hepatitis C" post="virus in HIV-infected patients in the interferon-free era: an"/>
  <result pre="era: an overview from south Spain. (1435â€&quot;4373 (Electronic)). 18.BerenguerJJarrÃ­nIPÃ©rez-LatorreLHontaÃ±Ã³nVVivancosMJNavarroJet al.Human" exact="Immunodeficiency" post="Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible,"/>
  <result pre="GutiÃ©rrez F, Blanco JR, Santos I, et al. Incidence of" exact="Hepatitis" post="C Virus (HCV) in a Multicenter Cohort of HIV-Positive"/>
  <result pre="PLoS One. 2014;9(12). 10.1371/journal.pone.0116226. 20.Rivero-JuarezALopez-CortesLFCastaÃ±oMMerinoDMarquezMManceboMet al.Impact of universal access to" exact="hepatitis C" post="therapy on HIV-infected patients: implementation of the Spanish national"/>
  <result pre="C therapy on HIV-infected patients: implementation of the Spanish national" exact="hepatitis C" post="strategyEur J Clin Microbiol Infect Dis201736348749410.1007/s10096-016-2822-627787664 21.Vickerman P, Martin"/>
  <result pre="Hickman M, Hickman M. Understanding the trends in HIV and" exact="hepatitis C" post="prevalence amongst injecting drug users in different settings--implications for"/>
  <result pre="M, Sabin C, Nelson M, Cooke GS, et al. Can" exact="Hepatitis" post="C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse"/>
  <result pre="Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV" exact="Epidemic" post="Among Men Who Have Sex With Men in the"/>
  <result pre="al. Behavioural, not biological, factors drive the HCV epidemic among" exact="HIV-positive" post="MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention"/>
  <result pre="Zahnd C, Wandeler G, Battegay M, Darling KE, et al." exact="Hepatitis" post="C virus transmission among human immunodeficiency virus-infected men who"/>
  <result pre="Darling KE, et al. Hepatitis C virus transmission among human" exact="immunodeficiency" post="virus-infected men who have sex with men: Modeling the"/>
  <result pre="of a short-term intensive intervention to interrupt HCV transmission in" exact="HIV-positive" post="men who have sex with men: a mathematical modelling"/>
  <result pre="men who have sex with men: a mathematical modelling studyJ" exact="Viral" post="Hepat2017251101810.1111/jvh.1275228685917 28.BerenguerJRiveroAJarrÃ­nINÃºÃ±ezMJVivancosMJCrespoMet al.Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in"/>
  <result pre="with men: a mathematical modelling studyJ Viral Hepat2017251101810.1111/jvh.1275228685917 28.BerenguerJRiveroAJarrÃ­nINÃºÃ±ezMJVivancosMJCrespoMet al.Human" exact="Immunodeficiency" post="Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient"/>
  <result pre="Martinez-Sapina AM, Rodriguez MJ, et al. Prevalence and distribution of" exact="hepatitis C" post="virus genotypes in Spain during the 2000â€&quot;2015 period (the"/>
  <result pre="period (the GEHEP 005 study). (1365â€&quot;2893 (Electronic)). 31.AspinallEJCorsonSDoyleJSGrebelyJHutchinsonSJDoreGJet al.Treatment of" exact="Hepatitis" post="C Virus Infection Among People Who Are Actively Injecting"/>
  <result pre="005 study). (1365â€&quot;2893 (Electronic)). 31.AspinallEJCorsonSDoyleJSGrebelyJHutchinsonSJDoreGJet al.Treatment of Hepatitis C Virus" exact="Infection" post="Among People Who Are Actively Injecting Drugs: A Systematic"/>
  <result pre="Review and Meta-analysisClin Infect Dis201357suppl_2S80SS910.1093/cid/cit30623884071 32.DaviesASinghKPShubberZduCrosPMillsEJCookeGet al.Treatment Outcomes of Treatment-NaÃ¯ve" exact="Hepatitis" post="C Patients Co-Infected with HIV: A Systematic Review and"/>
  <result pre="Wu Z, Wu Z. Methadone maintenance treatment and mortality in" exact="HIV-positive" post="people who inject opioids in China. (1564â€&quot;0604 (Electronic)). 36.Amin"/>
  <result pre="Dore GJ, Dore GJ. Causes of death after diagnosis of" exact="hepatitis" post="B or hepatitis C infection: a large community-based linkage"/>
  <result pre="GJ. Causes of death after diagnosis of hepatitis B or" exact="hepatitis C" post="infection: a large community-based linkage study. (1474-547X (Electronic)). 37.Thein"/>
  <result pre="Gj Fau - Krahn MD, Krahn MD. Natural history of" exact="hepatitis C" post="virus infection in HIV-infected individuals and the impact of"/>
  <result pre="- Krahn MD, Krahn MD. Natural history of hepatitis C" exact="virus infection" post="in HIV-infected individuals and the impact of HIV in"/>
  <result pre="Krahn MD, Krahn MD. Natural history of hepatitis C virus" exact="infection" post="in HIV-infected individuals and the impact of HIV in"/>
  <result pre="- Dillon JF, et al. HCV treatment rates and sustained" exact="viral" post="response among people who inject drugs in seven UK"/>
  <result pre="systematic review and meta-analysis. (1564â€&quot;0604 (Electronic)). 45.CohenMSChenYQMcCauleyMGambleTHosseinipourMCKumarasamyNet al.Prevention of HIV-1" exact="infection" post="with early antiretroviral therapyN Engl J Med2011365649350510.1056/NEJMoa110524321767103 46.Daar ES,"/>
  <result pre="Fau - Chernoff D, et al. Relation between HIV-1 and" exact="hepatitis C" post="viral load in patients with hemophilia. (1525â€&quot;4135 (Print)). 47.Polis"/>
  <result pre="Chernoff D, et al. Relation between HIV-1 and hepatitis C" exact="viral" post="load in patients with hemophilia. (1525â€&quot;4135 (Print)). 47.Polis CB,"/>
  <result pre="Impact of maternal HIV coinfection on the vertical transmission of" exact="hepatitis C" post="virus: a meta-analysis. (1537â€&quot;6591 (Electronic)). 48.Micallef JM, Kaldor Jm"/>
  <result pre="48.Micallef JM, Kaldor Jm Fau - Dore GJ, Dore GJ." exact="Spontaneous" post="viral clearance following acute hepatitis C infection: a systematic"/>
  <result pre="JM, Kaldor Jm Fau - Dore GJ, Dore GJ. Spontaneous" exact="viral" post="clearance following acute hepatitis C infection: a systematic review"/>
  <result pre="Fau - Dore GJ, Dore GJ. Spontaneous viral clearance following" exact="acute" post="hepatitis C infection: a systematic review of longitudinal studies."/>
  <result pre="- Dore GJ, Dore GJ. Spontaneous viral clearance following acute" exact="hepatitis C" post="infection: a systematic review of longitudinal studies. (1352â€&quot;0504 (Print))."/>
  <result pre="longitudinal studies. (1352â€&quot;0504 (Print)). 49.GrebelyJRaffaJDLaiCKrajdenMConwayBTyndallMWFactors associated with spontaneous clearance of" exact="hepatitis C" post="virus among illicit drug usersCan J Gastroenterol200721744745110.1155/2007/79632517637948 50.Instituto de"/>
  <result pre="in Spain in 2013. (1473â€&quot;5571 (Electronic)). 54.HaganHJordanAENeurerJClelandCMIncidence of sexually transmitted" exact="hepatitis C" post="virus infection in HIV-positive men who have sex with"/>
  <result pre="in 2013. (1473â€&quot;5571 (Electronic)). 54.HaganHJordanAENeurerJClelandCMIncidence of sexually transmitted hepatitis C" exact="virus infection" post="in HIV-positive men who have sex with menAIDS (London,"/>
  <result pre="2013. (1473â€&quot;5571 (Electronic)). 54.HaganHJordanAENeurerJClelandCMIncidence of sexually transmitted hepatitis C virus" exact="infection" post="in HIV-positive men who have sex with menAIDS (London,"/>
  <result pre="(Electronic)). 54.HaganHJordanAENeurerJClelandCMIncidence of sexually transmitted hepatitis C virus infection in" exact="HIV-positive" post="men who have sex with menAIDS (London, England)201529172335234510.1097/QAD.0000000000000834 55.BerenguerJGil-MartinÃ�JarrinIMontesMLDomÃ­nguezLAldÃ¡miz-EchevarrÃ­aTet"/>
  <result pre="who have sex with menAIDS (London, England)201529172335234510.1097/QAD.0000000000000834 55.BerenguerJGil-MartinÃ�JarrinIMontesMLDomÃ­nguezLAldÃ¡miz-EchevarrÃ­aTet al.Reinfection by" exact="hepatitis C" post="virus following effective all-oral direct-acting antiviral drug therapy in"/>
  <result pre="56.Eurostat. 2016. Available from: https://ec.europa.eu/eurostat/tgm/refreshTableAction.do?tab=table&amp;amp;plugin=1&amp;amp;pcode=tgs00101&amp;amp;language=de. 57.NeukamKVicianaPOjeda-BurgosGDelgado-FernÃ¡ndezMRÃ­osMJMacÃ­asJet al.No evidence of firstly" exact="acquired" post="acute hepatitis C virus infection outbreak among HIV-infected patients"/>
  <result pre="2016. Available from: https://ec.europa.eu/eurostat/tgm/refreshTableAction.do?tab=table&amp;amp;plugin=1&amp;amp;pcode=tgs00101&amp;amp;language=de. 57.NeukamKVicianaPOjeda-BurgosGDelgado-FernÃ¡ndezMRÃ­osMJMacÃ­asJet al.No evidence of firstly acquired" exact="acute" post="hepatitis C virus infection outbreak among HIV-infected patients from"/>
  <result pre="Available from: https://ec.europa.eu/eurostat/tgm/refreshTableAction.do?tab=table&amp;amp;plugin=1&amp;amp;pcode=tgs00101&amp;amp;language=de. 57.NeukamKVicianaPOjeda-BurgosGDelgado-FernÃ¡ndezMRÃ­osMJMacÃ­asJet al.No evidence of firstly acquired acute" exact="hepatitis C" post="virus infection outbreak among HIV-infected patients from southern Spain:"/>
  <result pre="https://ec.europa.eu/eurostat/tgm/refreshTableAction.do?tab=table&amp;amp;plugin=1&amp;amp;pcode=tgs00101&amp;amp;language=de. 57.NeukamKVicianaPOjeda-BurgosGDelgado-FernÃ¡ndezMRÃ­osMJMacÃ­asJet al.No evidence of firstly acquired acute hepatitis C" exact="virus infection" post="outbreak among HIV-infected patients from southern Spain: a multicentric"/>
  <result pre="57.NeukamKVicianaPOjeda-BurgosGDelgado-FernÃ¡ndezMRÃ­osMJMacÃ­asJet al.No evidence of firstly acquired acute hepatitis C virus" exact="infection" post="outbreak among HIV-infected patients from southern Spain: a multicentric"/>
  <result pre="Puro V Fau - Ippolito G, Ippolito G. Risk of" exact="hepatitis C" post="virus transmission following percutaneous exposure in healthcare workers. (0300â€&quot;8126"/>
  <result pre="C Fau - Thomas T, et al. Risk factors for" exact="hepatitis C" post="virus transmission to health care workers after occupational exposure:"/>
  <result pre="Decreasing prevalence of HCV coinfection in all risk groups for" exact="HIV infection" post="between 2004 and 2011 in Spain. (1365â€&quot;2893 (Electronic)). 61.Martin"/>
  <result pre="prevalence of HCV coinfection in all risk groups for HIV" exact="infection" post="between 2004 and 2011 in Spain. (1365â€&quot;2893 (Electronic)). 61.Martin"/>
  <result pre="JF, Craine N, et al. HCV treatment rates and sustained" exact="viral" post="response among people who inject drugs in seven UK"/>
  <result pre="sites: real world results and modelling of treatment impact. J" exact="Viral" post="Hepatol. 2015; (1365â€&quot;2893 (Electronic)). 62.JamalidoustMNamayandehMMoghadamiMZiyaeyanMComparison of HCV viral load"/>
  <result pre="impact. J Viral Hepatol. 2015; (1365â€&quot;2893 (Electronic)). 62.JamalidoustMNamayandehMMoghadamiMZiyaeyanMComparison of HCV" exact="viral" post="load and its genotype distributions in HCV mono- and"/>
  <result pre="HIV/HCV co-infected illicit drug usersVirol J201714112710.1186/s12985-017-0797-228697809 63.PerlmanDCDes JarlaisDCFeelemyerJCan HIV and" exact="hepatitis C" post="virus infection be eliminated among persons who inject drugs?J"/>
  <result pre="illicit drug usersVirol J201714112710.1186/s12985-017-0797-228697809 63.PerlmanDCDes JarlaisDCFeelemyerJCan HIV and hepatitis C" exact="virus infection" post="be eliminated among persons who inject drugs?J Addict Dis2015342â€&quot;319820510.1080/10550887.2015.105911126075647"/>
  <result pre="drug usersVirol J201714112710.1186/s12985-017-0797-228697809 63.PerlmanDCDes JarlaisDCFeelemyerJCan HIV and hepatitis C virus" exact="infection" post="be eliminated among persons who inject drugs?J Addict Dis2015342â€&quot;319820510.1080/10550887.2015.105911126075647"/>
  <result pre="among persons who inject drugs?J Addict Dis2015342â€&quot;319820510.1080/10550887.2015.105911126075647 64.WhiteEFGarfeinRSBrouwerKCLozadaRRamosRFirestone-CruzMet al.Prevalence of" exact="hepatitis C" post="virus and HIV infection among injection drug users in"/>
  <result pre="drugs?J Addict Dis2015342â€&quot;319820510.1080/10550887.2015.105911126075647 64.WhiteEFGarfeinRSBrouwerKCLozadaRRamosRFirestone-CruzMet al.Prevalence of hepatitis C virus and" exact="HIV infection" post="among injection drug users in two Mexican cities bordering"/>
  <result pre="Addict Dis2015342â€&quot;319820510.1080/10550887.2015.105911126075647 64.WhiteEFGarfeinRSBrouwerKCLozadaRRamosRFirestone-CruzMet al.Prevalence of hepatitis C virus and HIV" exact="infection" post="among injection drug users in two Mexican cities bordering"/>
  <result pre="Jarlais Dc Fau - Lelutiu-Weinberger C, Lelutiu-Weinberger C. Meta-regression of" exact="hepatitis C" post="virus infection in relation to time since onset of"/>
  <result pre="Fau - Lelutiu-Weinberger C, Lelutiu-Weinberger C. Meta-regression of hepatitis C" exact="virus infection" post="in relation to time since onset of illicit drug"/>
  <result pre="- Lelutiu-Weinberger C, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus" exact="infection" post="in relation to time since onset of illicit drug"/>
  <result pre="G, Berger A, Bruisten S, Rockstroh JK. Phylogenetic analysis of" exact="acute" post="hepatitis C virus genotype 4 infections among human immunodeficiency"/>
  <result pre="Berger A, Bruisten S, Rockstroh JK. Phylogenetic analysis of acute" exact="hepatitis C" post="virus genotype 4 infections among human immunodeficiency virus-positive men"/>
  <result pre="JK. Phylogenetic analysis of acute hepatitis C virus genotype 4" exact="infections" post="among human immunodeficiency virus-positive men who have sex with"/>
  <result pre="of acute hepatitis C virus genotype 4 infections among human" exact="immunodeficiency" post="virus-positive men who have sex with men in Germany."/>
  <result pre="Liver Int. 2010;8 (1478â€&quot;3231 (Electronic)). 67.de BruijneJSchinkelJPrinsMKoekkoekSMAronsonSJvan BallegooijenMWet al.Emergence of" exact="hepatitis C" post="virus genotype 4: phylogenetic analysis reveals three distinct epidemiological"/>
  <result pre="distinct epidemiological profilesJ Clin Microbiol200947123832383810.1128/JCM.01146-0919794040 68.MatthewsGVPhamSTHellardMGrebelyJZhangLOonAet al.Patterns and characteristics of" exact="hepatitis C" post="transmission clusters among HIV-positive and HIV-negative individuals in the"/>
  <result pre="68.MatthewsGVPhamSTHellardMGrebelyJZhangLOonAet al.Patterns and characteristics of hepatitis C transmission clusters among" exact="HIV-positive" post="and HIV-negative individuals in the Australian trial in acute"/>
  <result pre="among HIV-positive and HIV-negative individuals in the Australian trial in" exact="acute" post="hepatitis CClin Infect Dis201152680381110.1093/cid/ciq20021282185 69.DodgeJLTerraultNASexual transmission of hepatitis C:"/>
  <result pre="HIV-positive and HIV-negative individuals in the Australian trial in acute" exact="hepatitis" post="CClin Infect Dis201152680381110.1093/cid/ciq20021282185 69.DodgeJLTerraultNASexual transmission of hepatitis C: a"/>
  <result pre="trial in acute hepatitis CClin Infect Dis201152680381110.1093/cid/ciq20021282185 69.DodgeJLTerraultNASexual transmission of" exact="hepatitis" post="C: a rare event among heterosexual couplesJ Coagul Disord201441383926617979"/>
  <result pre="event among heterosexual couplesJ Coagul Disord201441383926617979 70.TerraultNADodgeJLMurphyELTavisJEKissALevinTRet al.Sexual transmission of" exact="hepatitis C" post="virus among monogamous heterosexual couples: the HCV partners studyHepatology201357388188910.1002/hep.2616423175457"/>
  <result pre="M. Needle syringe programmes and opioid substitution therapy for preventing" exact="hepatitis C" post="transmission in people who inject drugs. findingsfrom a Cochrane"/>
 </snippets>
</snippetsTree>
